These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii. Vu K; Gelli A Med Mycol; 2010 Mar; 48(2):255-62. PubMed ID: 19572230 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant effect of synthetic oligodeoxyribonucleotides (CpG-ODN) from the Paracoccidioides brasiliensis gp43 gene on the Th2-Th1 immunomodulation of experimental paracoccidioidomycosis. Amaral CC; Garcia IP; Fernandes GF; Almeida SR; Camargo ZP; Souza MC Scand J Immunol; 2005 Oct; 62(4):325-33. PubMed ID: 16253119 [TBL] [Abstract][Full Text] [Related]
10. STAT1 signaling within macrophages is required for antifungal activity against Cryptococcus neoformans. Leopold Wager CM; Hole CR; Wozniak KL; Olszewski MA; Mueller M; Wormley FL Infect Immun; 2015 Dec; 83(12):4513-27. PubMed ID: 26351277 [TBL] [Abstract][Full Text] [Related]
11. [Clinical study on fluconazole (FLCZ) in the treatment of primary pulmonary cryptococcosis]. Hayashi Y; Ito G; Takeyama S Kansenshogaku Zasshi; 1998 Dec; 72(12):1261-8. PubMed ID: 9916411 [TBL] [Abstract][Full Text] [Related]
12. Deoxynucleic acids from Cryptococcus neoformans activate myeloid dendritic cells via a TLR9-dependent pathway. Nakamura K; Miyazato A; Xiao G; Hatta M; Inden K; Aoyagi T; Shiratori K; Takeda K; Akira S; Saijo S; Iwakura Y; Adachi Y; Ohno N; Suzuki K; Fujita J; Kaku M; Kawakami K J Immunol; 2008 Mar; 180(6):4067-74. PubMed ID: 18322216 [TBL] [Abstract][Full Text] [Related]
14. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Ioannou XP; Gomis SM; Karvonen B; Hecker R; Babiuk LA; van Drunen Littel-van den Hurk S Vaccine; 2002 Nov; 21(1-2):127-37. PubMed ID: 12443671 [TBL] [Abstract][Full Text] [Related]
15. Additive potential of combination therapy against cryptococcosis employing a novel amphotericin B and fluconazole loaded dual delivery system. Khan AA; Alanazi AM; Jabeen M; Khan S; Malik A Eur J Pharm Sci; 2018 Jul; 119():171-178. PubMed ID: 29653177 [TBL] [Abstract][Full Text] [Related]
16. Prophylactic role of liposomized chloroquine against murine cryptococcosis less susceptible to fluconazole. Khan MA; Jabeen R; Mohammad O Pharm Res; 2004 Dec; 21(12):2207-12. PubMed ID: 15648251 [TBL] [Abstract][Full Text] [Related]
17. Role of AFR1, an ABC transporter-encoding gene, in the in vivo response to fluconazole and virulence of Cryptococcus neoformans. Sanguinetti M; Posteraro B; La Sorda M; Torelli R; Fiori B; Santangelo R; Delogu G; Fadda G Infect Immun; 2006 Feb; 74(2):1352-9. PubMed ID: 16428784 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen. Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509 [TBL] [Abstract][Full Text] [Related]
19. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis. Sane SA; Shakya N; Haq W; Gupta S J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Schwarz P; Dromer F; Lortholary O; Dannaoui E Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]